Bigmar Receives Product Approvals From the FDA.

JOHNSTOWN, Ohio--(BUSINESS WIRE)--March 1, 1999--BIGMAR, INC. (Nasdaq SmallCap Market:BGMR/Boston Stock Exchange: BGM) today announced that it has received its first Abbreviated New Drug Application ("ANDA") approvals from the Food and Drug Administration ("FDA") for the following products:

-- Methotrexate for Injection USP, 1g/vial (lyophilized)

-- Methotrexate Injection USP, 25 mg/mL, (Preserved)

-- Methotrexate Injection USP, 25 mg/mL, (Preservative-free)

-- Leucovorin Calcium for Injection USP, 200 mg/vial (lyophilized)

-- Leucovorin Calcium for Injection USP, 500 mg/vial (lyophilized)

The Methotrexate products are indicated in the treatment of various neoplastic diseases. The Leucovorin products are used to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection, 500 mg is also indicated in combination with 5-fluorouracil in the palliative treatment of patients with advanced colorectal cancer.

John G. Tramontana, Chairman of the Board and Chief Executive Officer, noted, "With the achievement of this important milestone, Bigmar is well positioned to begin introducing its drug products to the U.S. market. We will now have a truly global marketing presence, as U.S. distribution efforts complement sales activities already realized throughout Europe."

Mr. Tramontana also commented, "Not only does the large number of initial ANDA approvals create significant marketing momentum, the approval of Leucovorin Calcium for Injection USP, 500 mg provides an unique proprietary position, as Bigmar will be the first to offer this configuration in the United States. This product configuration was the subject of an earlier suitability petition approved by FDA. Approval of this product represents an important step in addressing the specific dosage needs of the patient population who depend on them."

Peter Stoelzle, Executive Vice President added, "Bigmar is now one of only a handful of facilities worldwide to utilize barrier isolation technology to manufacture FDA approved parenteral drug products and the only manufacturer to apply this highly automated containment technology to the manufacture of generic drugs. Aseptic processing experts agree that this technology, where personnel and the outer environment are separated from exposed sterile products and packaging components, can be superior to traditional aseptic clean room processing. It provides an opportunity to significantly reduce contamination rates during aseptic filling operations."

BIGMAR, Inc.'s strategy is to supply world markets with a full line of high-quality, affordably priced pharmaceutical products focusing on oncology. With distribution rights to more than 20 generic pharmaceutical products, the Company intends to manufacture, in its state-of-the-art facilities in Switzerland, and market, through pharmaceutical company partners in Europe and the United States, off-patent generic oncology drugs and additional drugs as their patents expire.

Forward-looking statements involve known and unknown risks, uncertainties and other factors as detailed in the Company's SEC reports and filings, which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied in such forward-looking statements.